Ebenbuild Gains €2.3M to Boost AI Health Tech for Lungs
Funding for Digital Healthcare Innovation
Ebenbuild has recently secured a significant Euro 2.3 million grant under the European Innovation Council (EIC) Accelerator program. This funding aims to propel the company's advancements in digital twin technology specifically tailored for respiratory health applications.
Market Potential for In Silico Trials
The digital health sector, particularly in silico trials, holds immense market potential. Ebenbuild is positioning itself to tap into this burgeoning market, which is estimated to soar to Euro 15 billion. The funds from the EIC grant will facilitate the market launch of Twinhale, a pioneering software designed for pulmonary drug delivery.
Revolutionizing Clinical Decision Support
In recent years, the healthcare industry has witnessed a paradigm shift towards personalized medicine. Ebenbuild's Twinhale software is at the forefront of this change, empowering clinicians to make well-informed decisions about drug efficacy and safety.
Transforming Respiratory Care
Twinhale stands out as the first scalable simulation tool capable of generating physiologically accurate, patient-specific predictions of drug deposition in the lungs. This advanced capability aims to not only lower trial failure rates but also reduce costs and expedite the time-to-market for new therapies.
Collaborative Success Stories
Incorporating Twinhale into pilot studies with notable pharmaceutical companies such as PARI Pharma and Pieris Pharmaceuticals has yielded impressive results. The software exhibited a remarkable ability to predict local drug deposition accurately, surpassing what traditional models could offer.
Long-term Vision for Respiratory Health
Ebenbuild is backed by significant investors, ensuring a solid foundation as it continues to innovate. With aspirations to expand into clinical decision support systems (CDSS) and broader personalized medicine, the company is well-placed to contribute meaningfully to the projected 300 billion Euro market for these technologies by 2030.
Statements from Leadership
CEO Dr. Kei Müller encapsulates the company’s mission, stating, "Our vision is to become the leading health intelligence platform for respiratory diseases. Twinhale is just the beginning of a broader strategy to enhance respiratory care outcomes through technology." This sentiment is echoed by Dr. Maximilian Grill, who emphasizes the importance of data generated through Twinhale in influencing future regulatory pathways.
A Roadmap to Future Innovations
Ebenbuild's roadmap extends beyond current technologies. Future developments include a software application aimed at optimizing mechanical ventilation for patients with lung complications. This segment addresses a Euro 10 billion market characterized by strong clinical demand and the necessity for rapid feedback cycles.
About Ebenbuild
Operating in the health tech domain, Ebenbuild specializes in creating precise computer models of the lungs based on in-depth patient-specific data. Utilizing physics-based simulation, artificial intelligence, and data science, the company aims to support key decision-makers in the healthcare landscape and improve patient outcomes.
Frequently Asked Questions
What is the primary focus of Ebenbuild?
Ebenbuild focuses on developing digital twin technology for respiratory health, enhancing clinical decision-making and drug delivery strategies.
What is Twinhale?
Twinhale is a simulation tool that predicts how drugs are delivered to the lungs, aiming to improve clinical trials and patient outcomes.
How much funding did Ebenbuild secure?
Ebenbuild secured €2.3 million from the European Innovation Council to advance its digital twin technology.
What is the market size for in silico trials?
The in silico trials market is projected to grow to Euro 15 billion as it becomes integral to modern clinical practices.
Who are the key partners of Ebenbuild?
Ebenbuild collaborates with companies like PARI Pharma and Pieris Pharmaceuticals, showcasing the effectiveness of its Twinhale software.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.